PUBLISHER: 360iResearch | PRODUCT CODE: 1606697
PUBLISHER: 360iResearch | PRODUCT CODE: 1606697
Diabetic Macular Edema Treatment Market by Treatment (Corticosteroid Injections, Drugs, Laser Treatment), End-User (Hospitals, Ophthalmology Clinics) - Global Forecast 2025-2030
The Diabetic Macular Edema Treatment Market was valued at USD 2.97 billion in 2023, expected to reach USD 3.12 billion in 2024, and is projected to grow at a CAGR of 5.11%, to USD 4.22 billion by 2030.
Diabetic Macular Edema (DME) treatment market encompasses the development and deployment of therapeutic solutions aimed at managing swelling in the macula, a primary cause of vision impairment among diabetic patients. The necessity for effective DME treatments is underscored by the rising global prevalence of diabetes, which increases the incidence of associated ocular complications. These treatments are crucial for preserving vision, improving life quality, and reducing healthcare burdens related to diabetes. The application scope includes pharmacological interventions like anti-VEGF injections, corticosteroids, and laser therapy, predominantly used by healthcare providers in specialized ophthalmic centers and hospitals. Key growth drivers in this domain include increased awareness about diabetic retinopathy, advancements in therapeutic options, and supportive health policies facilitating treatment affordability and access. Additionally, the aging global population prone to diabetes catalyzes demand.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 2.97 billion |
| Estimated Year [2024] | USD 3.12 billion |
| Forecast Year [2030] | USD 4.22 billion |
| CAGR (%) | 5.11% |
Recent opportunities are emerging in patient-centric modalities such as sustained drug delivery systems and biologics, aligning with ongoing research in precision medicine. To leverage these, companies should invest in R&D and partnerships focusing on innovation in drug formulations and comprehensive treatment regimens. However, the market faces challenges like high costs of advanced therapies, reimbursement issues, and potential side effects of treatments that may restrain uptake. Regulatory hurdles can also slow the introduction of novel therapies into the market. Future innovation should focus on non-invasive treatment methods and integrated care approaches, potentially incorporating digital health technologies to enhance patient monitoring and outcomes. Insight into the competitive landscape reveals a fragmented market, with key players constantly striving for differentiation through technology advancement and strategic collaborations. Overall, the growth of the DME treatment market hinges on balancing innovation with accessibility, where embracing technological advancement and addressing patient affordability remain paramount for sustainable business growth.
Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetic Macular Edema Treatment Market
The Diabetic Macular Edema Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.
- Market Drivers
- Rising global prevalence of diabetes with increasing geriatric population
- Increasing awareness of diabetic retinopathy and diabetic macular edema
- Government-led initiatives to raise awareness about diabetic retinopathy
- Market Restraints
- High treatment costs of DME treatments
- Market Opportunities
- Increasing introduction of new and advanced treatment options
- Improved reimbursement policies and healthcare coverage for DME treatments
- Market Challenges
- Clinical trial design challenges for DME treatments
Porter's Five Forces: A Strategic Tool for Navigating the Diabetic Macular Edema Treatment Market
Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetic Macular Edema Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.
PESTLE Analysis: Navigating External Influences in the Diabetic Macular Edema Treatment Market
External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetic Macular Edema Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.
Market Share Analysis: Understanding the Competitive Landscape in the Diabetic Macular Edema Treatment Market
A detailed market share analysis in the Diabetic Macular Edema Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.
FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetic Macular Edema Treatment Market
The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetic Macular Edema Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.
Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetic Macular Edema Treatment Market
A strategic analysis of the Diabetic Macular Edema Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.
Key Company Profiles
The report delves into recent significant developments in the Diabetic Macular Edema Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adverum Biotechnologies, Aerpio Pharmaceuticals, Alcon Vision LLC, Alimera Sciences, Inc., Arctic Vision, Bausch & Lomb Incorporated, Chugai Pharmaceutical Co., Ltd., EyePoint Pharmaceuticals Inc. ., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Graybug Vision, Inc., KalVista Pharmaceuticals, Inc., Kodiak Sciences Inc, Kubota Pharmaceutical Holdings Co. Ltd., Novartis AG, Ocugen Inc., Oculis Holding AG, Ocuphire Pharma, Inc., Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd., and YD Life Science.
Market Segmentation & Coverage
This research report categorizes the Diabetic Macular Edema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Based on Treatment, market is studied across Corticosteroid Injections, Drugs, Laser Treatment, and Pharmacological Treatment.
- Based on End-User, market is studied across Hospitals and Ophthalmology Clinics.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
The report offers a comprehensive analysis of the market, covering key focus areas:
1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.
2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.
3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.
4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.
5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.
The report also answers critical questions to aid stakeholders in making informed decisions:
1. What is the current market size, and what is the forecasted growth?
2. Which products, segments, and regions offer the best investment opportunities?
3. What are the key technology trends and regulatory influences shaping the market?
4. How do leading vendors rank in terms of market share and competitive positioning?
5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising global prevalence of diabetes with increasing geriatric population
- 5.1.1.2. Increasing awareness of diabetic retinopathy and diabetic macular edema
- 5.1.1.3. Government-led initiatives to raise awareness about diabetic retinopathy
- 5.1.2. Restraints
- 5.1.2.1. High treatment costs of DME treatments
- 5.1.3. Opportunities
- 5.1.3.1. Increasing introduction of new and advanced treatment options
- 5.1.3.2. Improved reimbursement policies and healthcare coverage for DME treatments
- 5.1.4. Challenges
- 5.1.4.1. Clinical trial design challenges for DME treatments
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. Diabetic Macular Edema Treatment Market, by Treatment
- 6.1. Introduction
- 6.2. Corticosteroid Injections
- 6.3. Drugs
- 6.4. Laser Treatment
- 6.5. Pharmacological Treatment
7. Diabetic Macular Edema Treatment Market, by End-User
- 7.1. Introduction
- 7.2. Hospitals
- 7.3. Ophthalmology Clinics
8. Americas Diabetic Macular Edema Treatment Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
9. Asia-Pacific Diabetic Macular Edema Treatment Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
10. Europe, Middle East & Africa Diabetic Macular Edema Treatment Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
11. Competitive Landscape
- 11.1. Market Share Analysis, 2023
- 11.2. FPNV Positioning Matrix, 2023
- 11.3. Competitive Scenario Analysis
- 11.4. Strategy Analysis & Recommendation
Companies Mentioned
- 1. AbbVie Inc.
- 2. Adverum Biotechnologies
- 3. Aerpio Pharmaceuticals
- 4. Alcon Vision LLC
- 5. Alimera Sciences, Inc.
- 6. Arctic Vision
- 7. Bausch & Lomb Incorporated
- 8. Chugai Pharmaceutical Co., Ltd.
- 9. EyePoint Pharmaceuticals Inc. .
- 10. F. Hoffmann-La Roche Ltd.
- 11. Genentech, Inc.
- 12. GlaxoSmithKline PLC
- 13. Graybug Vision, Inc.
- 14. KalVista Pharmaceuticals, Inc.
- 15. Kodiak Sciences Inc
- 16. Kubota Pharmaceutical Holdings Co. Ltd.
- 17. Novartis AG
- 18. Ocugen Inc.
- 19. Oculis Holding AG
- 20. Ocuphire Pharma, Inc.
- 21. Oxurion NV
- 22. Pfizer Inc.
- 23. Regeneron Pharmaceuticals Inc
- 24. Teva Pharmaceutical Industries Ltd.
- 25. YD Life Science
LIST OF FIGURES
- FIGURE 1. DIABETIC MACULAR EDEMA TREATMENT MARKET RESEARCH PROCESS
- FIGURE 2. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 5. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
- FIGURE 7. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 8. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 9. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 10. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 11. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 12. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 13. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 14. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 15. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 18. DIABETIC MACULAR EDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 19. DIABETIC MACULAR EDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
- TABLE 1. DIABETIC MACULAR EDEMA TREATMENT MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 6. DIABETIC MACULAR EDEMA TREATMENT MARKET DYNAMICS
- TABLE 7. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 8. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 11. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 13. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 15. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 16. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 17. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 18. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 19. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 20. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 21. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 22. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 23. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 24. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 25. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 26. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 27. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 28. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 29. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 30. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 31. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 32. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 33. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 34. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 35. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 36. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 37. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 38. INDONESIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 39. INDONESIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 40. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 41. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 42. MALAYSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 43. MALAYSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 44. PHILIPPINES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 45. PHILIPPINES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 46. SINGAPORE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 47. SINGAPORE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 48. SOUTH KOREA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 49. SOUTH KOREA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 50. TAIWAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 51. TAIWAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 52. THAILAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 53. THAILAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 54. VIETNAM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 55. VIETNAM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 56. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 57. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 58. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 59. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 60. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 61. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 62. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 63. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 64. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 65. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 66. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 67. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 68. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 69. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 70. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 71. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 72. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 73. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 74. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 75. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 76. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 77. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 78. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 79. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 80. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 81. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 82. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 83. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 84. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 85. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 86. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 87. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 88. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 89. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 90. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 91. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 92. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 93. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 94. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 95. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 96. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 97. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 98. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 99. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 100. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 101. DIABETIC MACULAR EDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 102. DIABETIC MACULAR EDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
